@Millionaire11 agreed. Natural should be a no-brainer, and elites def muddy up the clear path toward natural options, but I’m still hopeful for $TRUFF + $FLHLF. Have some of $CMPS too and want to see it pop in the short term. In the long-term, I’d like to see something botanically grown win - especially if it is already widely utilized 🤞
$CMPS
Feel free to shun me off the boards, but just here to chime in for support of psilocybin candidates as a whole 🤗:
$TRUFF +$FLHLF are still have the only naturally derived psilocybin candidate, with 50-70 clinical sites utilizing it, as well as multiple phase 2 studies running concurrently across 14+ indications.
They are no Compass, and I want Compass to succeed ENORMOUSLY, but when ppl start understanding how truly hard it is to standardize and get approval for treatment from botanical sources, they’ll see the light. Also blowing past multiple phase 2 studies may help in this regard.
Their extraction patents are gold standard and it’ll be hard for any company to match their reputation in the world of botanically grown.
Ultimately, it’s a whole lot cheaper to grow in the field than in the lab, and they’re currently building an 85K sqr foot facility for shroom harvest 🍄
My bet is on Compass for blaring reasons, but don’t sleep on $TRUFF & $FLHLF 🚀
@leLu83 I’m just here to chime in on $TRUFF +$FLHLF being the only naturally derived psilocybin candidate, with 50-70 clinical sites utilizing it, as well as multiple phase 2 studies running concurrently 😊
They might not be Compass today, but they might just might be soon positive progression through Phase 2. Their extraction patents are gold standard and it’ll be hard for any company to match their reputation in the world of botanically grown. I’ll take that land over arrows, any and every day 🌄
PS it’s a whole lot cheaper to grown in the field than in the lab, and they’re currently building an 85K sqr foot facility for shroom harvest 🍄
Magdalena Biosciences, the joint venture between Jaguar Health ( $JAGX) and Filament Health ( $FLHLF), has started a one‑month mouse study in Alberta testing a whole‑leaf coca extract as an appetite suppressant aimed at helping people maintain weight loss after GLP‑1 obesity drugs, marking its first obesity‑focused program on top of its broader plant‑based CNS pipeline.
https://prismmarketview.com/magdalena-biosciences-the-jaguar-health-filament-health-jv-has-begun-preclinical-tests-of-coca-based-appetite-suppressants/
$FLHLF I'm surprised this stock has so few followers. I wonder what might increase watchers? I would think the $JAGX crew would be at least low key interested considering the joint venture (Magdalena). Curious. 🤷🏻♀️
$FLHLF Research interest in the potential of psychedelic drugs to treat mental health conditions including depression, anxiety, existential distress in serious medical illnesses, post-traumatic stress disorder, and addiction has been growing. The U.S. Food and Drug Administration (FDA) granted “breakthrough therapy” designation to psilocybin-assisted psychotherapy for both major depressive disorder in 2019 and treatment-resistant depression in 2018. The FDA may also grant this designation for treatments for serious or life-threatening conditions where preliminary evidence suggests the treatment may improve the conditions substantially more than other available options.
$FLHLF Psychedelics are stepping out of the shadows and into the spotlight as some of the most promising tools in modern wellness and mental health. Once associated with the counterculture of the 1960s, these substances are now being rigorously studied for their potential to treat a range of mental health conditions, from depression to PTSD. The future of psychedelics is no longer a fringe idea—it’s becoming a mainstream reality with significant implications for how we approach mental well-being
$FLHLF these stock are currently extremely undervalued. When the market change they will get better. Read due diligance for the stock. And decide what you think. Phase 2 and 3 is always better for short term Performance.
